Boston Scientific Holds To Year-Long Guidance Despite Weak Sales In August
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific attributes lower than expected stent sales in August to Johnson & Johnson/Cordis' increased stent supply capacity rather than the European launch of Medtronic's Endeavor drug-eluting stent
You may also be interested in...
Medtronic Spotlights Endeavor Stent Launch Abroad, ICDs Domestically
Medtronic believes it can capture more than 15% of the international drug-eluting stent market within one year of rolling out its Endeavor in 40 countries outside the U.S
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.